Methods and compositions are disclosed for enhancing neurogenesis, resolving neuropathy and improving neurological health and functioning using fungal extracts and their active ingredients, including species of mushrooms and mycelia containing psilocybin and psilocin, combined with erinacines and hericenones or fungal extracts containing those active ingredients, with the addition of nicotinic acid. The compositions may optionally be combined with nervine plants.
DescriptionThis application claim the benefit under 35 USC 119(e) of U.S. provisional patent application Ser. No. 62/365,982, filed Jul. 23, 2016, currently co-pending, which is hereby incorporated by reference in its entirety.
The present invention relates to neuroregenerative compositions based upon constituents isolated from or contained within mushroom fruitbodies or mycelia, or the corresponding synthetic molecules, combined with niacin.
The current invention describes novel contributions to the field of medicinal mushroom research, particularly discoveries pertaining to neuroregeneration.
The tragedy of aging is the loss of accumulated knowledge due to neuropathy, especially related to dementia, Alzheimer's, and other neurological disorders. The cause of these disorders is a matter of dispute, ranging from free radical damage to exposure to toxins to inability of neurons to regenerate in the numbers and quality necessary for healthy mental functioning. In addressing a disease complex with multifactorial causes, offering a combination of elements which can synergistically repair and improve neurological function is an important step in helping cognitive and motor skills, in particular, as humans age and/or when exposed to neurotoxins, stress or head trauma. Not only are benefits realized from multiple active principle ingredients activating neurogenesis, but the compositions and methods below may additionally help mitigate and/or reverse ocular and cochlear nerve degeneration.
A composition including psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) or psilocin (4-hydroxy-N,N-dimethyltryptamine) in pure form or extracts from Psilocybe and psilocybin containing mushrooms combined with erinacines or hericenones, or extracts from Hericium mushroom species, and niacin (nicotinic acid or 3-pyridinecarboxylic acid, also known as vitamin B3), uniquely aids in repairing and improving neurologic functioning and signaling. (Schartner et al. (2017) reported substantial increased global neural signal diversity in a psilocybin-human clinical study (Nature Scientific Reports, 7:46421).) Additionally, niacin is known to be a neural anti-inflammatory, and, in itself, has been implicated in improving neural functioning. As niacin activates nerve endings, the inventor suggests that the addition of niacin contributes an added benefit by enhancing the neurogenic effects of psilocybin, psilocin, erinacines and hericenones by helping these nootropics cross the blood brain barrier, and migrate throughout the nervous systems, and to its end points. Moreover, niacin is a vasodilator improving blood flow in the brain by relaxing constricted blood vessels. This unique combination not only rebuilds myelin upon the axons, it also activates new astrocyte/astroglial cells and neuronal nodes of crossings such as the synaptic regions, particularly in the hippocampus. Other medicinal mushroom species also can be added, particularly species of Antrodia, Beauveria, Copelandia, Cordyceps, Ganoderma, Grifola, Inonotus, Isaria, Panaeolus, Phellinus, and other medicinal mushrooms and their mycelia whose unique neurogenerative properties may add benefits to this basic formulation. An excellent summary of the prior art related to the use of mushrooms as âbrain foodsâ can be found in Phan et al. (2017), âEdible and Medicinal Mushrooms: Emerging Brain Food for the Mitigation of Neurodegenerative Diseases,â Journal of Medicinal Foods 20(1): 1-10. Lion's Mane (Hericium erinaceus), Bear's Head (H. coralloides), or Comb Tooth (H. ramosum) mushrooms and mycelium have also been well studied and reported to regenerate myelin on the axons of nerves. Two particular families of compounds are most noteworthyâerinacines and hericenones. Erinacines, including known erinacines A-K, P and Q, are cyanthane terpenes isolated from the mycelia of Hericium erinaceus that promote NGF (nerve growth factor) synthesis. Hericenones, including known hericenones C-H, are cyanthane terpenes located in both the mycelia and fruiting body of Hericium erinaceus that promote NGF synthesis. Friedman et al. (2015) summarizes these activities in âChemistry, Nutrition, and Health-Promoting Properties of Hericium erinaceus (Lion's Mane) Mushroom Fruiting Bodies and Mycelia and Their Bioactive Compounds,â Journal of Agricultural and Food Chemistry 63: 7108-7123.
Although Phan et al. describes many species with potential neurogenerative properties, the psilocybin or psilocybian species (i.e. âpsilocybin-containingâ, from the use of âpsilocybienneâ as described by the French mycologist, Roger Heim, with R. Gordon Wasson, in 1957 in Les champignons hallucinogene du mexique. Paris: Museum de historie naturelle; 1958, pp. 268-71) are not mentioned, either alone or in combinations with the edible and medicinal mushroom species described by Phan. A good summary of the role of psilocybin in humans can be found in Passie et al. (2002), âThe Pharmacology of Psilocybin,â Addiction Biology 7: 357-364. That psilocybin has neurogenerative properties was elucidated by Catlow et al. (2013), âEffects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning,â Experimental Brain Research 228: 481-491.
The present nootropic invention can benefit those suffering from age or trauma related neuropathologies including but not limited to tinnitus, dementia, Alzheimer's, Parkinson's, Parkinsonism's, Multiple Sclerosis, atherosclerosis, trauma from accidents, exposure to neurotoxins (sarin, organophosphates and other toxic compounds), heavy metals, prions, amyloid plaque formation, demyelination, nerve signaling, neurotoxic viruses, stress and numerous other agents causing neuropathies. Psilocybian mushrooms, their enzymes and their indole alkaloids may counteract and reduce the toxicity of methyl phosphonatesâthe core structure of Sarin, a potent neurotoxin, used in nerve gases. Moreover, the use of psilocin and psilocybin in the compositions described here may help block the neurotoxicity effects of chemical nerve toxins and lead to protecting and healing military and civilians exposed to sarin and other neurotoxic agents. The use of fungal extracts also potentially enables neurogenesis by removing agents harmful to neurological health, including but not limited to parasites such as nematodes, protozoa, pathogenic bacteria, including Borrelia species and other spirochetes, and other infectious organisms or viruses. The benefits of this invention to the nervous system is hard to overstate. Additional benefits are conferred not only to humans challenged with diseases or neurotoxins, but also in healthy humans, including but not limited to increased cognitive function in students, scientists, computer coders, hackers, Big Data specialists, mathematicians, astronomers, strategic planners (i.e. such as in the U.S. Defense Department), gamers, linguists, writers, futurists, Mensa members, athletes, soldiers, religious leaders, politicians, business leaders or anyone benefitting from increased memory, intelligence, imagination, cognition, clairvoyance, motor skills, spatial navigation, athleticism, ability to more quickly respond to and process stimuli, balance, neuroplasticity, state of mind, longevity and mental health. Various benefits are also expected in vertebrate animals including mammals, carnivores, omnivores, herbivores, pets including cats and dogs and companion animals, farm and produce animals, laboratory animals, zoo animals, reptiles, fish and birds. The compounds of the present invention may also be useful for bees, including those suffering from pesticides, viruses or at risk from Colony Collapse Disorder, and various other invertebrates.
Niacin (nicotinic acid) has long been reported to counteract the effects of psilocybin and LSD, helping those experiencing adverse reactions or âbad tripsâ to return to a non-psychoactive state of mind, by reversing the excitement of nerve receptors. Therefore, the prior art teaches away from using niacin to excite nerve endings using psilocybin or psilocin. Hence, counter-intuitively, this invention uniquely combines niacin with psilocin/psilocybin and erinacines/hericenones for neurological restructuring and improved neurological health. By adding niacin into a psilocybin-centered neuroregenerative nootropic nutraceutical, vitamin complex or medicine in sufficient quantities to cause extreme discomfort for those who might try to abuse a therapeutic combination containing psilocin or psilocybin, this invention provides improved methods and compositions to prevent potential abuse by those wishing to get âhigh.â Analogous to effects of Antabuse (disulfiram), which induces an unpleasant experience for those abusing alcohol, the addition of sufficient quantities of niacin, which likewise causes extreme discomfort, with psilocybin/psilocin will help prevent the abuse of the described neurogenic formulas.
As little as 10-35 mg per day of niacin causes flushing redness on the skin, itchiness, burning and unpleasant tingling. Higher doses can lead to liver damage. 500 mg. per day is considered the top tier for safe use unless prescribed by a physician who closely monitors the patient for adverse effects. Some cholesterol-lowering products contain up to 500 milligrams of niacin and these levels can interfere with the metabolism of other medicines. 3,000 milligrams per day is clearly toxic. Upon hydrolysis, a drug called Picamilon produces GABA and niacin, allowing the inhibitory neurotransmitter GABA to pass through the blood-brain barrier. The addition of niacin to GABA to form nicotinyl-γ-aminobutyric acid or N-nicotinoyl-GABA also aids the passage of GABA across the blood-brain barrier. The stacking of niacin, psilocybin (or psilocin), GABA, erinacines and hericenones is an additional embodiment of this invention. Further embodiments include the addition of vanillic acid, trans-ferulic acid, trans-cinnamic acid, or other antiviral, anti-inflammatory polyphenols to reverse neuropathies, especially in those harmed by viruses such as, but not limited to, herpes simplex viruses (HSV), human papilloma viruses (HPV), polio, pox and other neurotoxic and inflammatory viruses.
Moreover by using psilocin or psilocybin at levels equivalent to what is colloquially known as âmicrodoses,â i.e. <1 mg per day for a 70 kg Individual, compounding effects can be realized over time. Such low doses have no noticeable consciousness altering effects on the person ingesting, and moreover, it is well know that tolerance to any perceived effects in altering one's consciousness is achieved very quickly from daily dosing of even higher levels, such as 10 mg of psilocin or psilocybin per day for a 70 kg person. Johns Hopkins researchers found the âsweet spotâ for full-blown therapeutic doses to be around 35 mg of psilocybin/psilocin for a 70 kg person. (Note that psilocybin is dephosphorylated into psilocin, which passes through the blood-brain barrier.)
The term âeffective amountâ or âtherapeutic amountâ refers to an amount sufficient to have neurogenerative activity. This amount may vary to some degree depending on the mode of administration, but will be in the same general range. The exact effective amount necessary could vary from subject to subject, depending on the compound, preventative treatment or condition being treated, the mode of administration, etc. The appropriate effective amount may be determined by one of ordinary skill in the art using only routine experimentation or prior knowledge in the art in view of the present disclosure. Note that effective ranges/dosages are not expected to be precisely the same for all compounds. Dosages may be optimized with each compound when the pharmacokinetics are studied to see how each compound is metabolized, which may alter the dose ranges. Nevertheless, given these factors, this neuro-enhancing invention is best managed in consultation with a skilled medical professional.
A suggested formula containing optional nervine plants that serves the purpose of neurological benefit but below any noticeable level of intoxication could be a 550 mg delivery dose via an ingestible capsule or by any means known to the art of drug delivery:
Plant extracts with known neuroregenerative properties include, but are not limited to:
Bacopaspecies (
Bacopa monnieri), Gotu kola (
Centella asiatica), and
Gingko(
Gingko biloba). Additional plants with anti-inflammatory properties include but are not limited to: Ginger (
Zingiber officinale), Holy Basil (
Ocimum sanctum), Hu Zhang (
Polygonum cuspidatum), Oregano (
Origanum vulgare, Origanum onites), Rosemary (
Rosmarinus officinalis, Rosmarinus eriocalyx, species in the genus
Rosmarinus), Turmeric (
Curcuma longa), Green Tea (
Camellia sinensis), lavender (
Lavandula spicaand related species in the genus
Lavandula), skullcap (
Scutellaria lateriflora) and oat straw (
Avena sativa, Avena byzantina). Moreover,
Salvia divinorum, aka Diviner's Sage, ayahuasca, a concoction made from
Banisteriopsis caapiand
Psychotriaspecies, and plants containing ibogaine (
Tabernanthe iboga, Voacanga africanaand
Tabernaemontana undulate), peyote (
Lophophora williamsii), the seeds of morning glory (
Ipomoea tricolorand related species) and Hawaiian baby woodrose (
Argyreia nervosa), and
Cannabis(
Cannabis sativa, C. indicaand
C. ruderalis), can be incorporated as well. Any nervine agents from natural products may also be incorporated, including, for example, cordycepin (or
Cordycepsextracts containing such) or amyloban (found in Lion's mane).
Depending on individual factors such as variations in metabolism, neurotransmitters and preventative treatment or condition, such a regimen of 500-1000 mg. of intake once to three times daily may produce measurable effects in one year, or the regimen may extend for up to a year or more before noticeable neurological benefits are evident. Since psilocybin converts to psilocin and is typically not detectable in the urine in 24 hours, the long term use of this nootropic formulation sustains psilocin as a serotonin agonist, while not activating dopamine receptors.
In another embodiment, the composition comprises one or more of ethyl 7-chloro-2-oxo-4-phenyl-2H-chromen-3-carboxylate, vanillic acid, chrysin, quercetin hydrate, rutin hydrate, syringic acid, trans-cinnamic acid, trans-ferulic acid, salts thereof, esters thereof, or combinations thereof, and thereby has an antiviral effect against a pathogenic virus comprising one or more of herpes Varicella zoster virus, Epstein-Barr virus, herpes simplex I and II viruses, human papillomaviruses (HPV), poliovirus, or viruses which contribute to neuropathies.
As ranges of these active ingredients can vary, the inventor anticipates the ranges giving benefits will include:
Compounds naturally produced by the mycelium of psilocybian mushrooms and their mycelium includes baeocystin, norbaeocystin, N,N-dimethyltryptamine, 5-hydroxytryptamine (serotonin), 5-hydroxytryptophan, psilocybin and psilocin. These compounds, their precursors and immediate derivatives are candidates for neurogenesis. Synthetic or natural prodrugs, congeners and analogs of psilocybin, psilocin, baeocystin and norbaeocystin may offer similar benefits. Congeners are chemical substances related to each other by origin, structure, or function. Analogs (or analogues or structural analogs) are compounds having a structure similar to another, but differing from it in respect of a certain substituent in which one or more atoms or functional groups which are replaced with other atoms or groups or substituents. Psilocybin and psilocin prodrugs and analogs that may similarly prove useful include those where the hydroxyl group is modified or the methyl groups of the terminal amine nitrogen have been modified. Example hydroxyl group substituents include alkyl and aryl ethers and esters, for example methoxy and ethoxy ethers and acetyl esters, halogens including fluoro-, chloro- and bromo-substituents, and thio groups such as methylthio or benzothio. Example nitrogen group substituents include one or both methyl groups substituted with ethyl, propyl, isopropyl, butyl, isobutyl, secbutyl, tertbutyl, amyl or allyl groups and the N-trimethyl analogs. The corresponding phosphate esters, namely psilocybin and baeocystin analogs, may also prove useful, as may analogs where one or more hydrogen atom is replaced by fluorine, chlorine or bromine. Also preferred, where possible, are the salts of the tryptamine compounds, for example hydrochloride, fumarate, maleate, picrate, oxalate, tartrate and sulfate salts, which are typically more stable. Also preferred are the zwitterionic forms, particularly of the phosphate esters and quaternary ammonium compounds. Preferred analogs include: 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT or O-Acetylpsilocin) the acetylated form of the psilocin (4-OH-DMT). It is a possible prodrug of psilocin (as are other 4-alkyl-esters), more stable than psilocin, and has a longer shelf life; 4-acetoxy-N-methyl-N-ethyltryptamine (4-AcO-MET), a psilocin analog substituted at R4 of its indole heterocycle with an acetoxy (AcO or CH3COOâ) functional group which also contains a methyl group and an ethyl chain bound to the terminal amine nitrogen of its tryptamine backbone. 4-AcO-MET is an acetate ester analog of 4-OH-MET and a N-substituted ethyl homolog of 4-AcO-DMT; 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET); 4-acetoxy-N-methyl-N-propyltryptamine (4-AcO-MPT); 4-acetoxy-N-methyl-N-isopropyltryptamine (4-AcO-MIPT); 4-acetoxy-N,N-dipropyltryptamine (4-AcO-DPT) and 4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DIPT); 4-hydroxy-N-methyl-N-ethyltryptamine (4-OH-MET, metocin or methylcybin), a 4-hydroxy N-substituted structural analog of psilocin and the with a methyl and an ethyl group bound to the terminal amine nitrogen of the tryptamine structure; 4-hydroxy-N-methyl-N-propyltryptamine (4-OH-MPT); 4-hydroxy-N-methyl-N-isopropyltryptamine (4-OH-MIPT); 4-hydroxy-N,N-diethyltryptamine (4-OH-DET); 4-hydroxy-N,N-dipropyltryptamine (4-OH-DPT); 4-hydroxy-N,N-diisopropyltryptamine (4-OH-DIPT); and 4-hydroxy-N,N-diallyltryptamine (4-OH-DALT): analogs where the 4-OH group has been removed, such as N,N-dimethyltryptamine (DMT), N-methyl-N-ethyltryptamine (MET), N-methyl-N-propyltryptamine (MPT), N,N-diethyltryptamine (DET), N,N-dipropyltriptamine (DPT), N,N-diisopropyltryptamine (DIPT), N-methyl-N-isopropyltryptamine (MIPT), a-methyl-tryptamine (AMT), N-ethyl-N-isopropyltryptamine (EIPT), N-methyl-N-butyl-tryptamine (MBT) or analogs substituted at other positions such as N,N-dimethyl-5-hydroxytryptamine (5-OH-DMT or bufotenine), 5-methoxy-a-methyltryptamine (5-MeO-aMT), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), 5-methoxy-N,N-diethyltryptamine (5-MeO-DET), 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT), 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), 5-methoxy-N-ethyl-N-isopropyltryptamine (5-MeO-EIPT), 2,a-dimethyltryptamine (2,a-DMT), a,N-dimethyltryptamine (a,N-DMT), a-ethyltryptamine (a-ET), 2-methyl-N,N-dimethyltryptamine (2-Me-DMT), 2-methyl-N,N-diethyltryptamine (2-Me-DET), 1-methylpsilocin and ibogaine (a complex tryptamine). In general, equimolar amounts of an analog may be used in place of psilocybin and/or psilocin in the formulas above, or amounts producing equivalent functional effects may be utilized. See TiHKAL: The Continuation by Alexander Shulgin and Ann Shulgin (1997, Transform Press) for an in-depth discussion of both âlegalâ analogs and âchemicalâ analogs, and synthesis and effects of various psilocybin and psilocin analogs.
Additional pharmaceutical excipients useful for the compositions as described herein include, for example, the following: Acidifying agents (acetic acid, glacial acetic acid, citric acid, fumaric acid, hydrochloric acid, diluted hydrochloric acid, malic acid, nitric acid, phosphoric acid, diluted phosphoric acid, sulfuric acid, tartaric acid); Alkalizing agents (ammonia solution, ammonium carbonate, diethanolamine, diisopropanolamine, potassium hydroxide, sodium bicarbonate, sodium borate, sodium carbonate, sodium hydroxide, trolamine); Antifoaming agents (dimethicone, simethicone); Antimicrobial preservatives (benzalkonium chloride, benzalkonium chloride solution, benzethonium chloride, benzoic acid, benzyl alcohol, butylparaben, cetylpyridinium chloride, chlorobutanol, chlorocresol, cresol, dehydroacetic acid, ethylparaben, methylparaben, methylparaben sodium, phenol, phenylethyl alcohol, phenylmercuric acetate, phenylmercuric nitrate, potassium benzoate, potassium sorbate, propylparaben, propylparaben sodium, sodium benzoate, sodium dehydroacetate, sodium propionate, sorbic acid, thimerosal, thymol); Antioxidants (ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorous acid, monothioglycerol, propyl gallate, sodium formaldehyde sulfoxylate, sodium metabisulfite, sodium thiosulfate, sulfur dioxide, tocopherol, tocopherols excipient); Buffering agents (acetic acid, ammonium carbonate, ammonium phosphate, boric acid, citric acid, lactic acid, phosphoric acid, potassium citrate, potassium metaphosphate, potassium phosphate monobasic, sodium acetate, sodium citrate, sodium lactate solution, dibasic sodium phosphate, monobasic sodium phosphate); Chelating agents (edetate disodium, ethylenediaminetetraacetic acid and salts, edetic acid); Coating agents (sodium carboxymethylcellulose, cellulose acetate, cellulose acetate phthalate, ethylcellulose, gelatin, pharmaceutical glaze, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, methacrylic acid copolymer, methylcellulose, polyvinyl acetate phthalate, shellac, sucrose, titanium dioxide, carnauba wax, microcrystalline wax, zein); Colorants (caramel, red, yellow, black or blends, ferric oxide); Complexing agents (ethylenediaminetetraacetic acid and salts (EDTA), edetic acid, gentisic acid ethanolamide, oxyquinoline sulfate); Desiccants (calcium chloride, calcium sulfate, silicon dioxide); Emulsifying and/or solubilizing agents (acacia, cholesterol, diethanolamine (adjunct), glyceryl monostearate, lanolin alcohols, mono- and di-glycerides, monoethanolamine (adjunct), lecithin, oleic acid (adjunct), oleyl alcohol (stabilizer), poloxamer, polyoxyethylene 50 stearate, polyoxyl 35 castor oil, polyoxyl 40 hydrogenated castor oil, polyoxyl 10 oleyl ether, polyoxyl 20 cetostearyl ether, polyoxyl 40 stearate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, diacetate, monostearate, sodium lauryl sulfate, sodium stearate, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, stearic acid, trolamine, emulsifying wax); Filtering aids (powdered cellulose, purified siliceous earth); Flavors and perfumes (anethole, benzaldehyde, ethyl vanillin, menthol, methyl salicylate, monosodium glutamate, orange flower oil, peppermint, peppermint oil, peppermint spirit, rose oil, stronger rose water, thymol, tolu balsam tincture, vanilla, vanilla tincture, vanillin); Humectants (glycerol, hexylene glycol, sorbitol); Plasticizers (e.g., castor oil, diacetylated monoglycerides, diethyl phthalate, glycerol, mono- and di-acetylated monoglycerides, propylene glycol, triacetin, triethyl citrate); Polymers (e.g., cellulose acetate, alkyl celluloses, hydroxyalkyl, acrylic polymers and copolymers); Solvents (acetone, alcohol, diluted alcohol, amylene hydrate, benzyl benzoate, butyl alcohol, carbon tetrachloride, chloroform, corn oil, cottonseed oil, ethyl acetate, glycerol, hexylene glycol, isopropyl alcohol, methyl alcohol, methylene chloride, methyl isobutyl ketone, mineral oil, peanut oil, propylene carbonate, sesame oil, water for injection, sterile water for injection, sterile water for irrigation, purified water); Sorbents (powdered cellulose, charcoal, purified siliceous earth); Carbon dioxide sorbents (barium hydroxide lime, soda lime); Stiffening agents (hydrogenated castor oil, cetostearyl alcohol, cetyl alcohol, cetyl esters wax, hard fat, paraffin, polyethylene excipient, stearyl alcohol, emulsifying wax, white wax, yellow wax); Suspending and/or viscosity-increasing agents (acacia, agar, alginic acid, aluminum monostearate, bentonite, purified bentonite, magma bentonite, carbomer, carboxymethylcellulose calcium, carboxymethylcellulose sodium, carboxymethylcellulose sodium 12, carrageenan, microcrystalline and carboxymethylcellulose sodium cellulose, dextrin, gelatin, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, magnesium aluminum silicate, methylcellulose, pectin, polyethylene oxide, polyvinyl alcohol, povidone, alginate, silicon dioxide, colloidal silicon dioxide, sodium alginate, tragacanth, xanthan gum); Sweetening agents (aspartame, dextrates, dextrose, excipient dextrose, fructose, mannitol, saccharin, calcium saccharin, sodium saccharin, sorbitol, solution sorbitol, sucrose, compressible sugar, confectioner's sugar, syrup); Surfactants (simethicone); Tablet binders (acacia, alginic acid, sodium carboxymethylcellulose, microcrystalline cellulose, dextrin, ethylcellulose, gelatin, liquid glucose, guar gum, hydroxypropyl methylcellulose, methylcellulose, polyethylene oxide, povidone, pregelatinized starch, syrup); Tablet and/or capsule diluents (calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate, microcrystalline cellulose, powdered cellulose, dextrates, dextrin, dextrose excipient, fructose, kaolin, lactose, mannitol, sorbitol, starch, pregelatinized starch, sucrose, compressible sugar, confectioner's sugar); Tablet disintegrants (alginic acid, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, starch, pregelatinized starch); Tablet and/or capsule lubricants (calcium stearate, glyceryl behenate, magnesium stearate, light mineral oil, sodium stearyl fumarate, stearic acid, purified stearic acid, talc, hydrogenated vegetable oil, zinc stearate); Thickening agents (gelatin having a Bloom strength of 50-100); Tonicity agent (dextrose, glycerol, mannitol, potassium chloride, sodium chloride); Vehicle: flavored and/or sweetened (aromatic elixir, compound benzaldehyde elixir, iso-alcoholic elixir, peppermint water, sorbitol solution, syrup, tolu balsam syrup); Vehicle: oleaginous (almond oil, corn oil, cottonseed oil, ethyl oleate, isopropyl myristate, isopropyl palmitate, mineral oil, light mineral oil, myristyl alcohol, octyl dodecanol, olive oil, peanut oil, persic oil, sesame oil, soybean oil, squalane); Vehicle: solid carrier (sugar spheres); Vehicle: sterile (Bacteriostatic water for injection, bacteriostatic sodium chloride injection); Viscosity-increasing (see suspending agent); Water repelling agents (cyclomethicone, dimethicone, simethicone); and/or solubilizing agent (benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, docusate sodium, nonoxynol 9, nonoxynol 10, octoxynol 9, poloxamer, polyoxyl 35 castor oil, polyoxyl 40, hydrogenated castor oil, polyoxyl 50 stearate, polyoxyl 10 oleyl ether, polyoxyl 20, cetostearyl ether, polyoxyl 40 stearate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, sodium lauryl sulfate, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, tyloxapol). This list is not meant to be exclusive, but instead merely representative of the classes of excipients and the particular excipients that may be used in oral dosage forms as described herein.
Another embodiment is methods for manufacturing a dosing form for treating, ameliorating, mitigating, alleviating, reducing and curing a nerve damage from neurotoxic virus infection comprising: formulating a composition into a dosage form comprising sprays, capsules, tablets, elixirs, emulsions, lozenges, suspensions, syrups, pills, lotions, epidermal patches, suppositories, inhalers, or injectables. Any methods known to the art for formulating extracts or active principal ingredients into lotions, soaps, etc. may be utilized.
Using blue light stimulation in the 280-400 nm wavelength range, precursor molecules to psilocybin and psilocin production can be elicited from the mycelium, primordia or fruitbodies of psilocybian or their close non-psilocybian relatives, to induce the formation of neurogenic compounds, including those that are not illegal, and therefore would not violate statutes in the United States or other countries. The goal here is to employ legal neurogenic precursor, congener or analog compounds related to psilocybin and psilocin.
Induction of bioactive compounds from mycelium through light stimulation is a method that can be used for discovering synergistic neurogenic compounds. Blue light activates shikimic acid production in mycelium, and antioxidant polyphenols, while also stimulating tyrosinase leading to melanization while inhibiting laccase and other enzymatic pathways, simultaneously inducing the production of psilocin, psilocybin and other tryptamines from mycelium in psilocybin active mushrooms and their relatives. Modifying the wavelength (i.e. blue light for 12 hours, red light for 12 hours, per day) and frequency of light exposure, including âpulsingâ of the light, can help articulate the expression of active neurogenic ingredients. The shikimic acid pathway gives rise to aromatic amino acids (phenylalanine, tyrosine and tryptophan), which are precursors for the formation of ergot alkaloids, lysergic acid, psilocybin and psilocin (Isaac, Fungal-Plant Interactions, Springer Netherlands, 1992). The inventor postulates that light stimulation evoking the transformation of ergosterol to vitamin D will also influence the pathways where light induces neurogenic compounds from mycelium. These pathways are interrelated and can be used for creating medically significant novel compositions whose synergy is useful for repairing the neuropathic damage by promoting neurogenesis and synaptic integrations. Exposure of mycelium to select wavelengths of light, especially blue and red spectra, may induce indole alkaloids related to psilocin analogues that have distinct antiviral and neuroprotective properties.
The biosynthesis of psilocybin from tryptophan involves enzymatic decarboxylation, methylation at the N9 position, 4-hydroxylation and O-phosphorylation. Light stimulation triggers the production of psilocybin and psilocin in the mycelium of, for instance Psilocybe azurescens, Psilocybe cyanescens and Psilocybe cubensis, possibly by stimulation of the enzymatic reactions. The âoff/onâ production of psilocybin, psilocin, baeocystin (the N-demethylated analog of psilocybin, 4-phosphoryloxy-N-methyltryptamine), norbaeocystin (the N-demethylated analog of psilocin, 4-phosphoryloxy-tryptamine) and other associated alkaloids from the mycelium caused by light exposure (particularly UV) are interrelated to the production of p-coumaric acid and the resultant metabolic expression of tyrosinase coding for melanin, especially prior to, during and after the time of primordia formation. The transition of the mycelium upon controlled light exposure, especially blue and UV light in the 280-420 nanometers ranges, affords the development of a customized suite of active ingredients, from which an extract be created or combined with active pharmacological molecules for a net benefit for the patient that consumes this unique combination.
Compositions and methods utilizing combinations of psilocin or psilocybin, and their immediate precursors, derived from mycelium that is exposed to light, particularly in the blue spectrum, additionally combined with erinacines or hericenones, with or without the addition of niacin, can result in medically significant, deliverable formulations for human consumption supporting neurogenesis.
This inventor reported Psilocybe azurescens to be the most potent psilocybian mushrooms in the world. (Stamets, P., Psilocybin Mushrooms of the World, 1996, Ten Speed Press.) A common side effect of taking this psychoactive mushroom species is loss of coordination and in some occasions, temporary paralysis. This mushroom contains ingredients related to psilocybin that may swamp receptor fields to cause these conditions. In medicine, the difference between a toxin and a medicine is often the dose. As such, this inventor suggests that other potent neurologically active ingredients are within Psilocybe azurescens (and to a lesser degree, Psilocybe cyanescens and Psilocybe subaeruginosa), which are likely useful for neurogenesis when presented or isolated at proper dosages.
Exposing mycelium grown on rice to blue and ultraviolet light in the 280-420 nanometer wavelengths, for a short window of time, lasting for a short duration of only 1-5 days, can help create and potentiate the neuroregenerative agents described herein. The intensity of light can range from 50-1,000 lux. By incubating the sterilized rice being actively colonized by the mycelium in plastic bags, which have grown out for a minimum of 1 week and up to 16 weeks, UV light exposure lights can be placed directly above and below horizontally shaped bags for maximum light exposure. The plastic bags or glass vessels can be selected for allowing these blue light wavelengths to reach the mycelium. The mycelium can undergo a phase-change in response to light stimuli into producing derivative neuroregenerative agents (it is to be expected that during this transitional period, the mycelium may contain varying mixtures of active compounds). This method and derivative improvements can potentiate the production of neuroregenerative molecules, some of which are intermediates during the melanization pathways activated by light exposure at specific wavelengths. This opens possibilities for customizing the output of specific active molecules using precise wavelengths, exposure times and intensities of light for manufacturing and potentiating production from mycelium. Lights can be pulsed and/or sequenced with varying wavelengths for exposing mycelium. The mycelium can also be subsequently agitated to cause new growth spurts, causing differentiation of hyphae with multiple nuclei per cell and hyper-expression of extracellular metabolites. Moreover, active molecules may be emitted differentially over time, allowing for windows of harvesting by washing the mycelium using cold EtOH and H2O or other solvents and processes known to the art of natural product extraction.
Serotonin is the fundamental neurotransmitter all animals use. That serotonin and psilocybin co-occur within psilocybin-containing (=âpsilocybianâ) mushrooms, and that psilocybin is a serotonin agonist, substituting for serotonin in the human brain and exciting neurotransmission, underscores the value of exploring these pathways for neurogenic compounds. Utilizing specific wavelengths of lightâboth blue and red spectraâcan induce or suppress expression of these compounds, allowing customization of neurogenic compounds which can be useful medically. Exposure of red light spectra on maturing mycelium of psilocybin active mushroom speciesâwhich naturally would generate psilocybin and psilocin in its myceliumâcan be used to acquire compounds useful for neurogenesis. Moreover, this unique combination of compounds can be incorporated into other therapies with such combinations providing unique advantages for medically significant advancements in repairing neurons, removing amyloid plaques, improving mental health, cognition, agility, and improving overall the ecology of consciousness. The inventor foresees utilizing such compounds in helping amputees activate their articulable prostheses. Such derivatives can help the improve cyborg technologies, allowing for neurons to grow into and mesh computer interfaces.
Moreover, the production of active principle ingredients from mycelium can be additionally enhanced by vibrational actions, including but not limited to pulsed sonic vibrationâsonificationâin combination with active principal ingredients stimulating UV wavelengths. Specific UV spectra and vibrations can be customized for enhancing yields.
Psilocybin dephosphorylates into psilocin in the liver, which then passes through the blood-brain barrier. Subsequent to enzymatic conversion and liver metabolism, psilocin is further degraded along at least one pathway, one rendition of which is featured below. These derivative compounds have neurogenic potential and are anticipated to be useful in nootropic formulations.
Moreover, since psilocin and its analogs are neurotransmitters, and substitute for serotonin, acting as an agonist exciting serotonin receptors, their ability to enhance neurotransmission while in combination with nerve growth factors such as erinacines and hericenones, provides a unique opportunity for spurring neurogenesis. When combined with niacin, which causes nerve ending excitement, and additionally combined with mushroom and plant extracts, compounded neurogenic benefits are anticipated by this inventor.
The inventor claims rights to obvious embodiments of this invention, including using delivery systems, compositions, combinations and solvent extraction methods as outlined in this author's previous patents and patent applications, which are a matter of record at the United States Patent and Trademark Office as well as methods and compositions known to the art of pharmaceutical science and drug discovery.
It will be apparent to one of ordinary skill in the relevant art that suitable modifications and adaptations to the compositions, formulations, methods, processes, and applications described herein can be made without departing from the scope of any embodiments or aspects thereof. The compositions and methods provided are exemplary and are not intended to limit the scope of any of the specified embodiments. All of the various embodiments, aspects, and options disclosed herein can be combined in any and all variations or iterations. The scope of the compositions, formulations, methods, and processes described herein include all actual or potential combinations of embodiments, aspects, options, examples, and preferences herein described. The exemplary compositions and formulations described herein may omit any component, substitute any component disclosed herein, or include any component disclosed elsewhere herein. The ratios of the mass of any component of any of the compositions or formulations disclosed herein to the mass of any other component in the formulation or to the total mass of the other components in the formulation are hereby disclosed as if they were expressly disclosed. Should the meaning of any terms in any of the patents or publications incorporated by reference conflict with the meaning of the terms used in this disclosure, the meanings of the terms or phrases in this disclosure are controlling. Furthermore, the foregoing discussion discloses and describes merely exemplary embodiments. All patents and publications cited herein are incorporated by reference herein for the specific teachings thereof.
No limitations with respect to the specific embodiments and examples disclosed herein are intended or should be inferred, as the examples and embodiments are representative only. While examples and preferred embodiments of the present invention have been shown and described, it will be apparent to those skilled in the art, or ascertainable using no more than routine experimentation, that many changes and modifications may be made without departing from the invention in its broader aspects. The appended claims are therefore intended to cover all such changes, modifications and equivalents as fall within the true spirit and scope of the invention.
1. A method for improving neurological health of an animal comprising: administering a therapeutically effective amount of a composition to an animal, wherein the composition comprises one or more of psilocybin, psilocin, baeocystin, norbaeocystin, salts thereof, or combinations thereof, one or more of erinacines, hericenones or combinations thereof, and niacin.
2. The method of claim 1 , wherein the animal is a human.
3. The method of claim 1 , wherein the composition additionally improves memory and cognition.
4. The method of claim 1 , wherein the composition additionally improves motor skills and coordination.
5. The method of claim 1 , wherein the composition additionally improves ability to solve complex computer coding challenges.
6. The method of claim 1 , wherein the composition additionally improves hearing.
7. The method of claim 1 , wherein the composition additionally improves vision.
8. The method of claim 1 , wherein the composition additionally improves sensory function.
9. The method of claim 1 , wherein the composition additionally improves learning.
10. The method of claim 1 , wherein the composition additionally promotes neurogenesis.
11. The method of claim 1 , wherein the composition additionally comprises one or more of (Bacopa monnieri), Gotu kola (Centella asiatica), Gingko (Gingko biloba), Ginger (Zingiber officinale), Holy Basil (Ocimum sanctum), Hu Zhang (Polygonum cuspidatum), Oregano (Origanum vulgare, Origanum onites), Rosemary (Rosmarinus officinalis, Rosmarinus eriocalyx, Rosmarinus species), Turmeric (Curcuma longa), Green Tea (Camellia sinensis), lavender (Lavandula spica and Lavandula species), skullcap (Scutellaria lateriflora), oat straw (Avena sativa and Avena byzantine), Diviner's Sage (Salvia divinorum), ayahuasca (Banisteriopsis caapi and Psychotria species), Tabernanthe iboga, Voacanga africana, Tabernaemontana undulate, peyote (Lophophora williamsii), morning glory (Ipomoea tricolor, Argyreia nervosa), Cannabis sativa, Cannabis indica or Cannabis ruderalis, or combinations thereof.
12. The method of claim 1 , wherein the composition additionally comprises one or more mycelium of Antrodia, Beauveria, Copelandia, Cordyceps, Ganoderma, Grifola, Hericium, Inonotus, Isaria, Panaeolus or Phellinus fungi, or combinations thereof; one or more extract of mycelium of Antrodia, Beauveria, Copelandia, Cordyceps, Ganoderma, Grifola, Hericium, Inonotus, Isaria Panaeolus or Phellinus, or combinations; one or more extract of Antrodia, Beauveria, Copelandia, Cordyceps, Ganoderma, Grifola, Hericium, Inonotus, Isaria, Panaeolus or Phellinus fruitbodies, or combinations thereof; or combinations thereof.
13. The method of claim 1 wherein the composition comprises one or more of extracted, isolated, synthetic or manufactured active compound, or combinations thereof.
14. A method for improving neurological health comprising: administering a daily dose of a composition for at least one month to a patient, wherein the composition comprises: one or more of about 0.1 to 10 mg of psilocybin, psilocin, baeocystin, norbaeocystin, or salts thereof, one or more of about 0.1 to 1 gram of psilocybin mushrooms, or combinations thereof; about 0.1 to 200 mg of one or more of erinacines, hericenones, or combinations thereof; and about 1 to 200 mg of niacin.
15. The method of claim 14 , wherein the composition comprises about 0.6 to 10 mg of one or more of psilocybin, psilocin, baeocystin, norbaeocystin, salts thereof, or combinations thereof, about 20 to 200 mg of one or more of erinacines, hericenones, or combinations thereof, and about 50 to 200 mg of niacin.
16. The method of claim 14 , wherein the composition comprises about 0.9 to 10 mg of one or more of psilocybin, psilocin, baeocystin, norbaeocystin, salts thereof, or combinations thereof, about 50 to 200 mg of one or more of erinacines, hericenones, or combinations thereof, and about 50 to 200 mg of niacin.
17. The method of claim 14 , wherein the composition additionally comprises one or more of (Bacopa monnieri), Gotu kola (Centella asiatica), Gingko (Gingko biloba), Ginger (Zingiber officinale), Holy Basil (Ocimum sanctum), Hu Zhang (Polygonum cuspidatum), Oregano (Origanum vulgare, Origanum onites), Rosemary (Rosmarinus officinalis, Rosmarinus eriocalyx, Rosmarinus species), Turmeric (Curcuma longa), Green Tea (Camellia sinensis), lavender (Lavandula spica and Lavandula species), skullcap (Scutellaria lateriflora), oat straw (Avena sativa and Avena byzantine), Diviner's Sage (Salvia divinorum), ayahuasca (Banisteriopsis caapi and Psychotria species), Tabernanthe iboga, Voacanga africana, Tabernaemontana undulate, peyote (Lophophora williamsii), morning glory (Ipomoea tricolor, Argyreia nervosa), Cannabis sativa, Cannabis indica or Cannabis ruderalis, or combinations thereof.
18. A method for improving neurological health of an animal comprising: administering a therapeutically effective amount of a composition to an animal, wherein the composition comprises: one or more of erinacines, hericenones, or combinations thereof; niacin; and one or more of N,N-dimethyltryptamine, 5-hydroxytryptamine, 5-hydroxytryptophan, 4-acetoxy-N,N-dimethyltryptamine, 4-acetoxy-N-methyl-N-ethyltryptamine, 4-acetoxy-N,N-diethyltryptamine, 4-acetoxy-N-methyl-N-propyltryptamine, 4-acetoxy-N-methyl-N-isopropyltryptamine, 4-acetoxy-N,N-dipropyltryptamine, 4-acetoxy-N,N-diisopropyltryptamine, 4-hydroxy-N-methyl-N-ethyltryptamine, 4-hydroxy-N-methyl-N-propyltryptamine, 4-hydroxy-N-methyl-N-isopropyltryptamine, 4-hydroxy-N, N-diisopropyltryptamine, 4-hydroxy-N,N-diisopropyltryptamine, 4-hydroxy-N-methyl-N-propyltryptamine, 4-hydroxy-N,N-diethyltryptamine, 4-hydroxy-N,N-diallyltryptamine, N-methyl-N-ethyltryptamine, N,N-diethyltryptamine, N,N-dipropyltriptamine, N,N-diisopropyltryptamine, N-methyl-N-propyltryptamine, N-methyl-N-isopropyltryptamine, a-methyl-tryptamine, N-ethyl-N-isopropyltryptamine, N-methyl-N-butyl-tryptamine, N,N-dimethyl-5-hydroxytryptamine, 5-methoxy-a-methyltryptamine, 5-methoxy-N,N-dimethyltryptamine, 5-methoxy-N,N-diethyltryptamine, 5-methoxy-N,N-dipropyltryptamine, 5-methoxy-N,N-diisopropyltryptamine, 5-methoxy-N-ethyl-N-isopropyltryptamine, 2,a-dimethyltryptamine, a,N-dimethyltryptamine, a-ethyltryptamine, 2-methyl-N, N-dimethyltryptamine, 2-methyl-N,N-diethyltryptamine, 1-methylpsilocin, ibogaine, 4-hydroxindole-3-acetylaldehyde, 4-hydroxtryptophol, 4-hydroxindole-3-acetic acid, salts thereof, or combinations thereof.
19. The method of claim 17 , wherein the animal is a human.
20. The method of claim 17 , wherein the composition additionally results in one or more of improved memory and cognition, improved motor skills and coordination, improved ability to solve complex computer coding challenges, improved hearing, improved vision, improved sensory function, improved learning or promotion of neurogenesis, or combinations thereof.
US15/494,503 2016-07-23 2017-04-23 Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin Abandoned US20180021326A1 (en) Priority Applications (20) Application Number Priority Date Filing Date Title US15/494,503 US20180021326A1 (en) 2016-07-23 2017-04-23 Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin US16/211,281 US11590120B2 (en) 2016-07-23 2018-12-06 Psilocybin compositions US16/285,457 US11471450B2 (en) 2016-07-23 2019-02-26 Psilocybin compositions US16/552,498 US11701348B1 (en) 2016-07-23 2019-08-27 Psilocybin compositions US16/992,631 US20200375967A1 (en) 2016-07-23 2020-08-13 Compositions of psilocybin and analogs US16/951,012 US20210069170A1 (en) 2016-07-23 2020-11-18 Tryptamine compositions for enhancing neurite outgrowth US17/308,869 US11896587B2 (en) 2016-07-23 2021-05-05 Tryptamine compositions for enhancing neurite outgrowth US17/480,789 US20220016104A1 (en) 2016-07-23 2021-09-21 Compositions and methods for treating depression US17/669,845 US20220313674A1 (en) 2016-07-23 2022-02-11 Psilocybin compositions US17/942,763 US20230024804A1 (en) 2016-07-23 2022-09-12 Psilocybin compositions US18/114,381 US20230218603A1 (en) 2016-07-23 2023-02-27 Psilocybin compositions US18/354,403 US20230355603A1 (en) 2016-07-23 2023-07-18 Psilocybin compositions US18/531,052 US20240122913A1 (en) 2016-07-23 2023-12-06 Tryptamine compositions for enhancing neurite outgrowth US18/531,407 US20240122914A1 (en) 2016-07-23 2023-12-06 Tryptamine compositions for enhancing neurite outgrowth US18/437,692 US20240189296A1 (en) 2016-07-23 2024-02-09 Tryptamine compositions for enhancing neurite outgrowth US18/611,130 US20240285606A1 (en) 2016-07-23 2024-03-20 Tryptamine compositions for enhancing neurite outgrowth US18/627,162 US20240285607A1 (en) 2016-07-23 2024-04-04 Tryptamine compositions for enhancing neurite outgrowth US18/627,244 US20240285608A1 (en) 2016-07-23 2024-04-04 Tryptamine compositions for enhancing neurite outgrowth US18/635,980 US20240285609A1 (en) 2016-07-23 2024-04-15 Tryptamine compositions for enhancing neurite outgrowth US18/636,026 US20240277691A1 (en) 2016-07-23 2024-04-15 Tryptamine compositions for enhancing neurite outgrowth Applications Claiming Priority (2) Application Number Priority Date Filing Date Title US201662365982P 2016-07-23 2016-07-23 US15/494,503 US20180021326A1 (en) 2016-07-23 2017-04-23 Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin Related Child Applications (1) Application Number Title Priority Date Filing Date US16/211,281 Continuation US11590120B2 (en) 2016-07-23 2018-12-06 Psilocybin compositions Publications (1) Family ID=60989805 Family Applications (8) Application Number Title Priority Date Filing Date US15/494,503 Abandoned US20180021326A1 (en) 2016-07-23 2017-04-23 Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin US16/211,281 Active US11590120B2 (en) 2016-07-23 2018-12-06 Psilocybin compositions US16/285,457 Active 2037-09-12 US11471450B2 (en) 2016-07-23 2019-02-26 Psilocybin compositions US16/992,631 Abandoned US20200375967A1 (en) 2016-07-23 2020-08-13 Compositions of psilocybin and analogs US17/480,789 Pending US20220016104A1 (en) 2016-07-23 2021-09-21 Compositions and methods for treating depression US17/669,845 Pending US20220313674A1 (en) 2016-07-23 2022-02-11 Psilocybin compositions US17/942,763 Abandoned US20230024804A1 (en) 2016-07-23 2022-09-12 Psilocybin compositions US18/114,381 Pending US20230218603A1 (en) 2016-07-23 2023-02-27 Psilocybin compositions Family Applications After (7) Application Number Title Priority Date Filing Date US16/211,281 Active US11590120B2 (en) 2016-07-23 2018-12-06 Psilocybin compositions US16/285,457 Active 2037-09-12 US11471450B2 (en) 2016-07-23 2019-02-26 Psilocybin compositions US16/992,631 Abandoned US20200375967A1 (en) 2016-07-23 2020-08-13 Compositions of psilocybin and analogs US17/480,789 Pending US20220016104A1 (en) 2016-07-23 2021-09-21 Compositions and methods for treating depression US17/669,845 Pending US20220313674A1 (en) 2016-07-23 2022-02-11 Psilocybin compositions US17/942,763 Abandoned US20230024804A1 (en) 2016-07-23 2022-09-12 Psilocybin compositions US18/114,381 Pending US20230218603A1 (en) 2016-07-23 2023-02-27 Psilocybin compositions Country Status (1) Cited By (46) * Cited by examiner, â Cited by third party Publication number Priority date Publication date Assignee Title US20190142851A1 (en) * 2017-11-16 2019-05-16 CaaMTech, LLC Compositions comprising a psilocybin derivative and a cannabinoid US10519175B2 (en) 2017-10-09 2019-12-31 Compass Pathways Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use CN111494435A (en) * 2019-01-30 2020-08-07 è¡èççæè¡ä»½æéå ¬å¸ Use of extract of mycelium of Hericium erinaceum for preparing medicinal composition for improving myelination of central nervous system WO2020212948A1 (en) * 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation US20210145851A1 (en) * 2019-11-19 2021-05-20 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth WO2021168082A1 (en) * 2020-02-18 2021-08-26 Gilgamesh Pharmaceuticals, Inc. Specific tryptamines for use in the treatment of mood disorders US20210267966A1 (en) * 2018-06-21 2021-09-02 Robert Joseph Petcavich Method of Inducing Dendritic and Synaptic Genesis in Neurodegenerative Chronic Diseases WO2021188812A1 (en) * 2020-03-19 2021-09-23 Caamtech, Inc. Crystalline norpsilocin compounds WO2021226041A1 (en) * 2020-05-04 2021-11-11 Caamtech, Inc. Crystalline dimethyl tryptamine analogues WO2021236759A3 (en) * 2020-05-20 2022-02-17 Caamtech, Inc. Crystalline 4-hydroxy-n,n-di-n-propyltryptammonium (4-ho-dpt) salts WO2022038299A1 (en) * 2020-08-21 2022-02-24 Compass Pathfinder Limited Novel psilocin derivatives having prodrug properties WO2022072808A1 (en) * 2020-10-01 2022-04-07 Mydecine Innovations Group Inc. Novel psychedelic compositions, delivery systems and therapeutic uses thereof US20220112162A1 (en) * 2019-08-25 2022-04-14 Caamtech, Inc. Alkyl quaternary ammonium tryptamines and their therapeutic uses US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof US11344510B2 (en) 2019-12-26 2022-05-31 Gilgamesh Pharmaceuticals, Inc. Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders WO2022120289A1 (en) * 2020-12-02 2022-06-09 The Johns Hopkins University Restoration of motor function post-neurological injury using psychedelics WO2022173584A1 (en) * 2021-02-09 2022-08-18 Caamtech, Inc. Crystalline 5-methoxy-dipropyl tryptamine compounds EP3917537A4 (en) * 2019-01-30 2022-09-07 Diamond Therapeutics Inc. COMPOSITIONS AND METHODS COMPRISING A 5HT RECEPTOR AGONIST FOR THE TREATMENT OF PSYCHOLOGICAL, COGNITIVE, BEHAVIORAL AND/OR MOOD DISORDERS US11471450B2 (en) 2016-07-23 2022-10-18 Turtle Bear Holdings, Llc Psilocybin compositions US11471439B2 (en) * 2017-02-09 2022-10-18 Caamtech, Inc. Compositions and methods comprising a combination of serotonergic drugs WO2022236130A1 (en) * 2021-05-07 2022-11-10 Turtle Bear Holdings, Llc Fungal compound compositions and methods for modulating inflammation US11518742B2 (en) 2020-06-12 2022-12-06 Beckley Psytech Limited Composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine WO2023023298A1 (en) * 2021-08-20 2023-02-23 Psilosterics, Llc Hallucinogenic and non-hallucinogenic compounds and methods of making and using the same US11591353B2 (en) 2020-02-04 2023-02-28 Mindset Pharma Inc. Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders CN115813917A (en) * 2022-11-02 2023-03-21 å¼ æ¨è¿ A compound capable of rapidly improving cognitive function and its application US11701348B1 (en) 2016-07-23 2023-07-18 Turtle Bear Holdings, Llc Psilocybin compositions EP4003395A4 (en) * 2019-07-23 2023-07-19 Caamtech, Inc. Compositions containing toad secretion compounds WO2023137094A1 (en) * 2022-01-12 2023-07-20 Eleusis Therapeutics Us, Inc. Psilocin benzoate formulation for intravenous infusion US11724985B2 (en) 2020-05-19 2023-08-15 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use EP4230195A1 (en) * 2019-03-07 2023-08-23 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations US11746087B1 (en) * 2022-03-18 2023-09-05 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using US11773063B1 (en) 2022-08-19 2023-10-03 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof US11819475B2 (en) 2017-02-09 2023-11-21 Caamtech, Inc. Compositions comprising a serotonergic tryptamine compound US11896587B2 (en) 2016-07-23 2024-02-13 Turtle Bear Holdings, Llp Tryptamine compositions for enhancing neurite outgrowth AU2021397252B2 (en) * 2020-12-09 2024-03-14 Caamtech, Inc. Dialkyl tryptamines and their therapeutic uses US11957659B2 (en) 2020-12-28 2024-04-16 Psilo Scientific Ltd. Transmucosal dephosphorylated psychoactive alkaloid composition and preparation thereof WO2024079647A1 (en) 2022-10-11 2024-04-18 Sintalica S.R.L. Composition comprising tryptamines and maois compounds selected from β-carboline inhibitors, and pharmaceutical uses thereof US12060328B2 (en) 2022-03-04 2024-08-13 Reset Pharmaceuticals, Inc. Co-crystals or salts of psilocybin and methods of treatment therewith CN118637829A (en) * 2024-08-14 2024-09-13 天津å é¢ç¨åç 究é¢æéè´£ä»»å ¬å¸ A water-purifying cerium-containing modified rare earth water-retaining glaze and preparation method thereof US12097184B2 (en) * 2021-03-06 2024-09-24 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability US12102616B2 (en) 2022-07-12 2024-10-01 Lobe Sciences Ltd. Psilocin mucate US12129234B1 (en) 2023-08-03 2024-10-29 Gilgamesh Pharmaceuticals, Inc. Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine US12157722B1 (en) 2023-08-03 2024-12-03 Gilgamesh Pharmaceuticals, Inc. Crystalline hydrochloride salts of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof US12344583B2 (en) 2024-09-18 2025-07-01 Lobe Sciences Ltd. Solid psilocin salts Families Citing this family (29) * Cited by examiner, â Cited by third party Publication number Priority date Publication date Assignee Title SG11202109111VA (en) 2019-02-27 2021-09-29 Univ California Azepino-indoles and other heterocycles for treating brain disorders JP2022550463A (en) 2019-10-01 2022-12-01 ã¨ã³ããªã¢ã³ ãã¥ã¼ããµã¤ã¨ã³ã¹ï¼ ã¤ã³ã³ã¼ãã¬ã¤ããã Genetic engineering of fungi to modulate tryptamine expression WO2021072530A1 (en) * 2019-10-15 2021-04-22 Tassili Life Sciences, Corp. Controlled release formulations of psilocybe-derived agents and method for their use, and methods and compositions for threating mild traumatic brain injury with post traumatic stress disorder. WO2021188782A1 (en) * 2020-03-19 2021-09-23 Caamtech, Inc. Crystalline psilacetin derivatives US12233355B2 (en) 2020-06-17 2025-02-25 Psilo Scientific Ltd. Methanol-based extraction of psychoactive alkaloids from fungus US11510952B2 (en) 2020-06-17 2022-11-29 Psilo Scientific Ltd. Ethanol extraction of psychoactive compounds from psilocybin fungus US11382942B2 (en) 2020-06-17 2022-07-12 Psilo Scientific Ltd. Extraction of psychoactive compounds from psilocybin fungus EP4161546A4 (en) 2020-06-17 2024-10-09 Psilo Scientific Ltd COMPOSITIONS WITH PSYCHOACTIVE COMPOUNDS FROM PSYCHOACTIVE ORGANISMS US11000534B1 (en) 2020-10-08 2021-05-11 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof US11324762B2 (en) 2020-10-08 2022-05-10 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof AU2021373520A1 (en) * 2020-11-06 2023-06-29 Mynd Life Sciences Inc. A method of treating depression by immune modulation WO2022150840A1 (en) * 2021-01-08 2022-07-14 Miami University Psilocybin and norbaeocystin compositions and methods of treatment AU2022206448B2 (en) * 2021-01-11 2024-04-18 Caamtech, Inc. Quaternary tryptamines and their therapeutic uses US20220331344A1 (en) * 2021-04-15 2022-10-20 Resurgent Biosciences, Inc Oral formulations of psychotropic macrofungus botanical extracts with mouthfeel experience enhancers EP4366731A4 (en) 2021-07-07 2025-04-16 Terran Biosciences Inc N,N-DIMETHYLTRYPTAMINE AND RELATED PSYCHEDELICS AND USES THEREOF US11344564B1 (en) 2021-08-20 2022-05-31 Lennham Pharmaceuticals, Inc. Method of treatment based on reduced monoamine oxidase a activity US20250011344A1 (en) * 2021-08-20 2025-01-09 Terran Biosciences Inc. Prodrugs and derivatives of psilocin and uses thereof WO2023044135A1 (en) * 2021-09-17 2023-03-23 1242753 Ontario Inc. Psilocybin derived compositions and methods of using same CA3133547A1 (en) 2021-10-07 2023-04-07 Psilo Scientific Ltd. Liquid-liquid extraction of purified psychoactive alkaloid US11911402B2 (en) * 2021-10-13 2024-02-27 ECP Pharma Methods of treatment with combinations of cannabidiol and psilocybin CA3134640C (en) * 2021-10-18 2023-12-12 Psilo Scientific Ltd. Purified psychoactive alkaloid extraction using acidified acetone EP4429672A4 (en) 2021-11-12 2025-04-30 Terran Biosciences Inc PSILOCYBIN AND O-ACETYLPSILOCIN, SALTS AND SOLID FORMS THEREOF WO2023108167A1 (en) * 2021-12-10 2023-06-15 Caamtech, Inc. Psilocybin derivatives KR20240150417A (en) 2021-12-15 2024-10-15 ë¸ë¦ì¤ í ë¼í¨í±ì¤, ì¸í¬. Psychoplastogens substituted with phenoxy and benzyloxy and their uses WO2023115060A1 (en) * 2021-12-17 2023-06-22 The Regents Of The University Of California Psychoplastogens for treating hearing-related disorders WO2023130078A2 (en) 2021-12-31 2023-07-06 Empyrean Neuroscience, Inc. Genetically modified mycelium for producing psychotropic alkaloids US20250066299A1 (en) * 2022-01-06 2025-02-27 Terran Biosciences Inc. Salts and solid forms of 4-hydroxy-n,n-diisopropyltryptamine hemi-glutarate and hemi-succinate WO2023164092A1 (en) * 2022-02-25 2023-08-31 Parow Entheobiosciences Llc Treatment of psychiatric disorders, brain injuries, and autism spectrum disorder WO2025038854A2 (en) * 2023-08-15 2025-02-20 The General Hospital Corporation Fiber optic detection system for delivery of photobiomodulation therapy Family Cites Families (26) * Cited by examiner, â Cited by third party Publication number Priority date Publication date Assignee Title US3075992A (en) 1958-09-12 1963-01-29 Sandoz Ltd Esters of indoles US3078214A (en) 1958-09-12 1963-02-19 Sandoz Ag Treatment of mental disturbances with esters of indoles US3192111A (en) 1959-02-16 1965-06-29 Sandoz Ltd Method of inducing therapeutic tranquilization with psilocybin and psilocin US20010008641A1 (en) 1998-11-25 2001-07-19 R. Douglas Krotzer Nutritionally active composition for bodybuilding US9399050B2 (en) 2000-10-04 2016-07-26 Paul Edward Stamets Controlling insects and arthropods using preconidial mycelium and extracts of preconidial mycelium from entomopathogenic fungi US9474776B2 (en) 2000-10-04 2016-10-25 Paul Edward Stamets Integrative fungal solutions for protecting bees US9931316B2 (en) 2004-01-06 2018-04-03 Paul Edward Stamets Antiviral activity from medicinal mushrooms and their active constituents JP4641942B2 (en) 2003-10-03 2011-03-02 ãã§ã¼ã¤ã¬ã³ã»ãã ãã¼ã¼ã»ãã§ã³ãã¼ãã·ã£ãã Use of compounds capable of increasing serum IGF-1 levels for the manufacture of therapeutic compositions for the treatment of various disease states associated with reduced IGF-1 serum levels in humans and animals US20060216331A1 (en) 2005-02-28 2006-09-28 Lines Thomas C Composition for treating mental health disorders KR100826446B1 (en) 2006-11-22 2008-04-29 ì¨ì ì´ì ì¼ì ë¹ (주) Functional mycelium production method of roe deer fungus with base of rice bran or red ginseng and functional mycelium of roe deer fungus containing active ingredient of rice bran or red ginseng GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament US20110206721A1 (en) 2010-02-19 2011-08-25 Vijaya Nair Fermented soy nutritional supplements including mushroom components BR112015002309A2 (en) * 2012-08-07 2017-07-04 Buck Inst Res Aging multi-component formulation to enhance neurological function US8609162B2 (en) 2012-10-04 2013-12-17 Invivo Beverages Llc Integrated neuromodulation system for mood enhancement of a living human subject US20160136225A1 (en) * 2013-06-19 2016-05-19 Stemtech International, Inc. Methods and compositions for enhancing stem cell mobilization IL273507B2 (en) 2014-06-30 2024-06-01 Syqe Medical Ltd Methods, devices and systems for administering active substances through the lungs EP2974731A1 (en) * 2014-07-18 2016-01-20 Hennig Arzneimittel GmbH&Co. Kg Administration form containing fungal components US10092609B2 (en) 2015-01-16 2018-10-09 James A. Wieser Process for preparing medicinal mycological preparations US20180021326A1 (en) 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin EP3506926A4 (en) 2016-07-26 2020-10-14 Flagship Pioneering Innovations V, Inc. Neuromodulating compositions and related therapeutic methods for the treatment of inflammatory and autoimmune diseases CA3052974A1 (en) 2017-02-09 2018-08-16 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative US20190142851A1 (en) 2017-11-16 2019-05-16 CaaMTech, LLC Compositions comprising a psilocybin derivative and a cannabinoid US11383084B2 (en) 2017-04-27 2022-07-12 Palo Alto Investors Treatment of dermatological conditions via neuromodulation EP4219445A1 (en) 2019-03-07 2023-08-02 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations CA3149602A1 (en) 2019-08-25 2021-03-04 Andrew R. Chadeayne Alkyl quarternary ammonium tryptamines and their therapeutic uses EP4121045A4 (en) 2020-03-19 2024-04-10 Caamtech, Inc. CRYSTALLINE NORPSILOCIN COMPOUNDSFree format text: FINAL REJECTION MAILED
2019-09-12 STCB Information on status: application discontinuationFree format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION
2021-04-07 AS AssignmentOwner name: TURTLE BEAR HOLDINGS, LLC, WASHINGTON
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:STAMETS, PAUL E.;REEL/FRAME:055960/0665
Effective date: 20210225
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.4
